A phase ib study of high-dose intermittent (HDI) afatinib in EGFR t790m mutation-positive non-small cell lung cancer patients with acquired resistance to reversible EGFR TKIS

作者： D Ross Camidge , Pasi A Jaenne , Lecia V Sequist , Vikram Chand , Elizabeth Dowling

DOI:

关键词: